PCR real time assays for the early detection of BKV-DNA in immunocompromised patients

Katia Marinelli1, Patrizia Bagnarelli1, Gianni Gaffi2, Silvia Trappolini3, Pietro Leoni3, Alessandra Mataloni Paggi4, Agnese Della Vittoria5, Giorgio Scalise3, Pietro Emanuele Varaldo1, Stefano Menzo1

1Istitito di Microbiologia e Scienze Biomediche, Università Politecnica delle Marche; 2Nefrologia e Dialisi, AO-Ospedali Riuniti Ancona; 3Ematologia clinica, AO-Ospedali Riuniti Ancona; 4Malattie Infettive, AO-Ospedali Riuniti Ancona; 5Clinica Malattie Infettive, AO-Ospedali Riuniti Ancona, Italy

SUMMARY

Testing for viral BKV-DNA in urine is a non-invasive early detection and monitoring tool in the diagnostic of BKV-related pathologies: quantitative analysis by Real-Time PCR can provide useful information in addition to cytopathologic analysis, although our study suggests that high BKV viruria is not necessarily associated with kidney or bladder damage.

KEY WORDS: Polyomavirus, Renal transplant, Nephropathy

BK virus (BKV) is a polyomavirus, ubiquitous in human populations: over 90% of adults worldwide are infected during early childhood (Hirsch 2002), mostly transmitted by the respiratory route (Goudsmit 1982, Sundsfjord 1994). After primary infection, asymptomatic in the majority of cases, BKV maintains low-level replication in different sites in the body, most frequently in the kidney (Heritage 1981); replication can occasionally surge to detectable levels in urine. In immunocompromised patients, viral reactivation is often followed by clinical disease. In particular, in patients who undergo hematopoietic stem cell transplantation (HSCT), reactivation of BKV infection is associated with hemorrhagic cystitis (incidence 15%) (Sencer 1993), while in kidney transplant recipients acute tubulointerstitial nephritis is more frequent (incidence 5-8%) (Randhawa 1999, Hirsch 2002B). Acute tubulointerstitial nephritis is accompanied by a reduced renal function and allograft failure occurs in over 10% of patients affected (Hirsch 2002B). The increasing incidence of disease associated with BKV in immunocompromised patients requires further studies for the diagnosis and the management of infection. In fact, BKV viruria is not per se predictive of disease, given the frequency of asymptomatic reactivation in immunocompromised patients, 30-40% (Mylonakis 2001). Some authors claim that viruria beyond the threshold of 10^7 copies/ml in urine can be a predictive marker of BKV pathology (Hirsch 2005). The aim of this study is to define the prevalence of BKV reactivations in different categories of immunocompromised patients, and to investigate the relationship between viral load in urine, immunosuppression and disease. We studied 120 consecutive immunocompromised patients followed at Ospedali Riuniti, Ancona between May 2006 and January 2007 by evaluating renal function (creatinine and nitrogen in blood, cytology of urine sediment, when available) and CD4+ T cell number.
Viral load was evaluated in urine by a Real-Time PCR technique. A qualitative PCR was also performed on all samples to exclude false negative results due to potential probe mismatches.

The patients were divided into three groups:

Group I: 70 HIV-positive (46 males, 24 females, aged 18-77 years, mean 43.4) all free from BKV-associated disease. They were classified on the basis of CD4+ T cell count into two subgroups; 21 patients with CD4+ T cell count <200/mm3 and 49 patients with CD4+ T cell count >200/mm3.

Group II: 12 kidney transplant recipients (9 males and 3 females, aged 1-74 years, mean 36) all free from BKV-associated disease.

Group III: 38 bone marrow transplant recipients (23 males, 15 females, aged 5-73 years, mean 43.8), five of whom had hemorrhagic cystitis.

Urine samples were collected from each patient and were centrifuged at 18000 rcf for 30 min. The sediment was re-suspended in 200 µl of lysis buffer containing EDTA 1mM, Tris-HCl 10mM pH 8.0, Tween 20 and NP40 (0.5% each) and 25 µg of proteinase K.

After incubation for 4 hours at 56°C and denaturation for 10 min at 94°C and then 45 cycles each of 95°C for 15 s and 60°C for 1 min. The standard curve for the quantification of BKV-DNA in sample was obtained by a 10-fold serial dilutions of the plasmid pBKV-VP1, obtained by inserting the 72 bp fragment amplified by the Q-PCR primers in the pGEM T-EasyTA vector (Promega). The procedure was performed following the manufacturer's instructions and, after transfection of JM109 competent cells, plasmid DNA from positive bacterial clones was purified by Wizard® Plus SV Minipreps, DNA purification system (Promega) and the DNA concentration was assessed by spectrophotometric analysis at 260 nm.

Primers for qualitative PCR targeted the BKV LT-Ag gene, and they were also designed after thorough alignment of BKV sequences for the identification of a conserved region; these sequences are (as synthesized): LT-Agf (forward primer: 5’ TAC AGC ATT TCC ATG AGC TC 3’), LT-Agr (reverse primer: 5’ GTA GAT ACC CTT CAT ATG AC 3’).

Quantitative-PCR (Q-PCR) was carried out by real-time amplification using the MX3000p (Stratagene) amplifier. PCR primers for the BKV VP1 gene were designed after thorough alignment of BKV sequences available in the GenBank database to identify a highly conserved region (including strains from different geographical areas).

The primer sequences are as follows (as synthesized): VP1f (forward primer: 5’ ACT GTA ACA CCT GCT CTT GAA GCA T 3’), VP1r (reverse primer: 5’AGC TGC CCC TGG ACA CTC T3’), and the TaqMan probe (5’ TGA AGA TGG CCC CAA CCA AAA GAA AAG 3’) dual-labelled at the 5’ end with 6-carboxyfluorescin (FAM) and the 3’ end with 6-carboxytetramethylrhodamine (TAMRA). Primers and probe were designed using the Primer Express® software (PE Biosystems).

Q-PCR amplifications were set up in a 25 µl reaction volume containing 12.5 µl of TaqMan Universal PCR Master Mix (PE Biosystems), 5 µl of sample, 2.5 µl of VP1f and VP1r 500 nM each and 2.5 µl of TaqMan probe 100 nM.

Thermal cycling conditions were: 2 min incubation at 50°C, followed by a 10 min at 95°C and then 45 cycles each of 95°C for 15 s and 60°C for 1 min. The overall prevalence of BKV reactivation in the population studied was 22.5%, the results are summarized in table I. In particular, the prevalence of BKV viruria in group I (HIV-positive) was 22.8% (16/70), however, reactivation occurred in 57% (12/21) of patients with CD4+ T cell number <200/mm3, in contrast to 8.2% (4/49) in those with >200. Nevertheless all subjects within this group were free from BKV-related disease and had normal renal function.
In group II, kidney transplant recipients, BKV DNA in urine was detected in only 3 patients (25%), but none displayed any sign of disease. One patient, despite a BKV DNA copy number exceeding $10^7$ copies/ml, was asymptomatic and had no altered marker of renal function. Finally, in group III, bone marrow transplant recipients, the prevalence of BKV viruria was 23.7% (9/38). Interestingly, in contrast to the other groups, 5 out of the 6 patients with BKV viruria exceeding $10^7$ copies/ml, suffered from hemorrhagic cystitis (severe hematuria and dysuria). During the period of surveillance a female patient entered the study at the onset of the cystitis. This 25-year-old, was transplanted in November 2006 and was treated with cyclosporine and micophenolate mofetil. Hemorrhagic cystitis occurred 40 days after transplantation. At the worsening of symptoms, 57 days after transplantation, cidofovir (a single 250mg dose) was administered to the patient, first by intravesical route, subsequently, at day 59, cidofovir was administered again, both intravesical (250mg) and intravenous (250 mg) achieving a two logarithm reduction in viruria (Figure 1). At the same time the dosage of the immunosuppressive therapy was increased to prevent a possible rejection. Despite the improvement of symptoms and the reduction of hematuria, viruria remained stable (3 subsequent determinations, mean value $2\times10^8$ copies/ml) up to 80 days after transplantation. Plasma samples were also evaluated in this case and BKV load in plasma was also stable (day 77:

![Figure 1 - Clinical course and blood/urine viral load in patient with hemorrhagic cystitis.](image)

**TABLE 1 - Prevalence of BKV in urine samples from different immunocompromised patients.**

<table>
<thead>
<tr>
<th>Group I: HIV-positive</th>
<th>CD4 n. (%)</th>
<th>Viruria</th>
<th>Viruria &gt;10^7</th>
<th>Media viral load</th>
<th>Altered renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;200</td>
<td>21 (30%)</td>
<td>12 (57%)</td>
<td>6 (50%)</td>
<td>6x10^8</td>
<td>0</td>
</tr>
<tr>
<td>&gt;200</td>
<td>49 (70%)</td>
<td>4 (8,2%)</td>
<td>1 (25%)</td>
<td>2x10^5</td>
<td>0</td>
</tr>
</tbody>
</table>

| Group II: kidney transplant | nd | 12 | 3 (25%) | 1 (33,3%) | 4x10^8 | 4 |

| Group III: bone marrow transplant | <200 | 38 | 9 (23,7%) | 6 (66,6%) | 4x10^9 | 3 |
3x10^5 copies/ml, day 79: 2.7x10^5 copies/ml) (Figure 1).

In conclusion, the following evidence emerged from this study: BKV reactivation occurs at comparable frequency in the different groups of immunocompromised patients, mean value 22.5%.

However, in HIV positive patients with CD4+ T cell number <200, reactivation is more frequent (mean value 57%) than in transplant recipients who are generally more immunosuppressed and have CD4+ T cell mostly <200. Interestingly the level of viruria is inversely correlated with CD4+ T cell counts (p 0.03 Spearman Correlation). Reactivations in HIV positive patients, despite being very frequent, do not seem to progress to clinical disease. In contrast, in bone marrow transplant recipients, the high viral load (>10^7 copies/ml in urine) is relatively rare but correlates with the occurrence of hemorrhagic cystitis. The same threshold did not appear to be a reliable predictive marker of BKV related nephropathy, either in HIV+ or in hematologic patients. Further studies are needed to clarify these aspects and to understand the role of viruria in the pathogenesis of BKV-related disease in different categories of immunocompromised patients.

REFERENCES


